Jiangsu Kanion Pharmaceutical Co Ltd Market Cap ($1.05 Billion)
Market Cap & Net Worth: Jiangsu Kanion Pharmaceutical Co Ltd (600557)
Jiangsu Kanion Pharmaceutical Co Ltd market cap. Jiangsu Kanion Pharmaceutical Co Ltd (SHG:600557) has a market capitalization of $1.05 Billion (CN¥7.21 Billion) as of November 9, 2026. Listed on the SHG stock exchange, this China-based company holds position #8367 globally and #1921 in its home market, demonstrating a 5.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Kanion Pharmaceutical Co Ltd's stock price CN¥12.73 by its total outstanding shares 566158806 (566.16 Million). Also see 600557 cash flow metrics for how efficiently the company converts equity into cash flow.
Jiangsu Kanion Pharmaceutical Co Ltd Market Cap History (2015–2026)
Jiangsu Kanion Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows change from $1.68 Billion to $1.05 Billion (-3.47% CAGR). Check 600557 share price today for real-time trading data and today's change.
Jiangsu Kanion Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Kanion Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 600557 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.29x
Jiangsu Kanion Pharmaceutical Co Ltd's market cap is 0.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.88x
Jiangsu Kanion Pharmaceutical Co Ltd's market cap is 2.88 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.68 Billion | $2.82 Billion | $362.34 Million | 0.60x | 4.65x |
| 2016 | $1.37 Billion | $3.00 Billion | $373.74 Million | 0.46x | 3.68x |
| 2017 | $1.10 Billion | $3.27 Billion | $373.78 Million | 0.34x | 2.94x |
| 2018 | $841.96 Million | $3.82 Billion | $414.05 Million | 0.22x | 2.03x |
| 2019 | $1.21 Billion | $4.57 Billion | $506.99 Million | 0.27x | 2.40x |
| 2020 | $842.55 Million | $3.03 Billion | $262.92 Million | 0.28x | 3.20x |
| 2021 | $1.01 Billion | $3.65 Billion | $320.54 Million | 0.28x | 3.16x |
| 2022 | $1.55 Billion | $4.35 Billion | $434.47 Million | 0.36x | 3.58x |
| 2023 | $1.70 Billion | $4.86 Billion | $464.16 Million | 0.35x | 3.66x |
| 2024 | $1.13 Billion | $3.90 Billion | $391.86 Million | 0.29x | 2.88x |
Competitor Companies of 600557 by Market Capitalization
Companies near Jiangsu Kanion Pharmaceutical Co Ltd in the global market cap rankings as of November 9, 2026. Also see how large is Jiangsu Kanion Pharmaceutical Co Ltd's balance sheet for a full breakdown of the balance sheet.
Key companies related to Jiangsu Kanion Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Jiangsu Kanion Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Jiangsu Kanion Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Jiangsu Kanion Pharmaceutical Co Ltd's market cap moved from $1.68 Billion to $ 1.05 Billion, with a yearly change of -3.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.05 Billion | -9.78% |
| 2025 | CN¥1.17 Billion | +3.60% |
| 2024 | CN¥1.13 Billion | -33.63% |
| 2023 | CN¥1.70 Billion | +9.44% |
| 2022 | CN¥1.55 Billion | +53.19% |
| 2021 | CN¥1.01 Billion | +20.35% |
| 2020 | CN¥842.55 Million | -30.62% |
| 2019 | CN¥1.21 Billion | +44.23% |
| 2018 | CN¥841.96 Million | -23.37% |
| 2017 | CN¥1.10 Billion | -20.08% |
| 2016 | CN¥1.37 Billion | -18.41% |
| 2015 | CN¥1.68 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 9th, 2026 the market cap of Jiangsu Kanion Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.05 Billion USD |
| MoneyControl | $1.05 Billion USD |
| MarketWatch | $1.05 Billion USD |
| marketcap.company | $1.05 Billion USD |
| Reuters | $1.05 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It also offers medicines in the fields of anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others. In addition, the company provides herb extracts and formula granules, as well as OEM/ODM services. Jiangsu Kanion Pharmaceutical Co.,Ltd. was founded in 1975 a… Read more